

WHO Medical Product Alert N°2/2024: Falsified OZEMPIC CRM:0557503

Dear Dr Nicknam,

I am writing to kindly inform you about the WHO Medical Product Alert N°2/2024 related to falsified OZEMPIC (semaglutide) identified in the WHO Regions of Americas and Europe which is available through the below link. It will also be available soon in all 6 UN languages on the WHO website.

[https://www.who.int/news/item/19-06-2024-medical-product-alert-n-2-2024--falsified-ozempic-\(semaglutide\)](https://www.who.int/news/item/19-06-2024-medical-product-alert-n-2-2024--falsified-ozempic-(semaglutide))

While noting that WHO calls for increased security for these products, you are kindly requested to share this information with the relevant departments of the Ministry of Health and Medical Education as well as National Regulatory Authority and procurement institutions.

If you have any questions or if you wish to report incidents concerning falsified or substandard medical products, please contact rapidalert@who.int and copy langarh@who.int and nuseirata@who.int.

Thank you.

Yours Sincerely,



Dr Syed Jaffar Hussain
Country Representative and Head of Mission
World Health Organization, I.R. Iran

Dr Mohammad Hossein Nicknam
Director General for International Affairs
MOHME, I.R. Iran

WHO Country Office in the Islamic Republic of Iran

Bldg. of Ministry of Health & Medical Education, Eyvanak blvd., Phase Five, Shahrak-e-Qods, Tehran, 14665 - Iran. | Tel: (+98-21) 88 36 37 18 | (+98-21) 88 36 39 79 - 80 | Fax: (+98-21) 88 36 41 00

نمایندگی سازمان جهانی بهداشت در جمهوری اسلامی ایران

تهران، شهرک قدس، فاز پنج، بلوار ایوانک شرقی، ساختمان وزارت بهداشت، درمان و آموزش پزشکی. کد پستی: ۱۴۶۷۶۶۴۹۶۱ | تلفن: (+۹۸-۲۱) ۸۸۳۶ ۳۷ ۱۸ | (+۹۸-۲۱) ۸۸۳۶ ۳۹ ۷۹ - ۸۰ | فکس: (+۹۸-۲۱) ۸۸۳۶ ۴۱ ۰۰